Lyell started at Buy by Wainwright

 

• HC Wainwright initiated coverage of Lyell Immunopharma Inc 
  LYEL+2.60%+ Free Alerts
   with a Buy rating and a price target of $12 per share. 
• Lyell leverages two ex vivo epigenetic reprogramming technologies, Gen-R and Epi-R, which are designed to generate T-cell populations that are more effective and resilient. 
• The analyst believes the technologies position Lyell as a solid tumor cell therapy leader.
• LYL845 is a tumor-infiltrating lymphocyte (TIL) therapy designed to incorporate the Epi-R technology. 
• HC Wainwright says LYL845 design can potentially help overcome challenges associated with competing TIL products, including limited efficacy due to poor enrichment of tumor-reactive T cells, poor quality and growth potential of expanded T cells, and failure to maintain polyclonality of TILs during production. 
• Earlier this month, the FDA cleared the Investigational New Drug application to initiate a Phase 1 trial for LYL845. 
• Patient screening for the Phase 1 trial is set to begin over the coming months, and initial clinical data is expected in 2024.

https://www.benzinga.com/analyst-ratings/analyst-color/22/10/29292239/analyst-sees-a-leader-in-solid-tumor-cell-therapy-in-this-stock